This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.
The study uses an ambispective design, including both retrospective and prospective data collection. Autoimmune pancreatitis (AIP) remains a diagnostic challenge due to its heterogeneous clinical presentation and overlap with pancreatic cancer and other inflammatory conditions. The Odesa Criteria 2026 (OC26) were developed as a flexible, domain-based point scoring system integrating four diagnostic domains: morphology, serology, clinical features, and histology. Each domain contributes weighted points toward a total diagnostic score, enabling structured and reproducible assessment across diverse patient phenotypes. This ambispective observational study evaluates the diagnostic performance of OC26 in real-world clinical practice. The study assesses sensitivity, specificity, predictive values, likelihood ratios, and overall diagnostic accuracy using final clinical diagnosis as the reference standard. Additional analyses include interobserver agreement for domain scoring, diagnostic performance of individual domains, ROC curve analysis for the total OC26 score, and determination of the optimal diagnostic cut-off. The study aims to validate OC26 as a practical, scalable, and reproducible diagnostic tool for autoimmune pancreatitis, supporting its implementation in routine clinical workflows and future international guideline development.
Study Type
OBSERVATIONAL
Enrollment
82
Participants receive no assigned intervention. Diagnostic evaluation follows routine clinical practice.
Military Medical Clinical Center of the Southern Region
Odesa, Ukraine
RECRUITINGMilitary Medical Clinical Center of the Southern Region
Odesa, Ukraine
RECRUITINGDiagnostic accuracy of the Odesa Criteria 2026 (OC26) as a domain-based scoring system for autoimmune pancreatitis
Evaluation of the diagnostic performance of the Odesa Criteria 2026 (OC26), a domain-based point scoring system for autoimmune pancreatitis (AIP). The analysis includes calculation of sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios, and overall diagnostic accuracy using final clinical diagnosis as the reference standard.
Time frame: At completion of baseline diagnostic assessment
Interobserver agreement for OC26 domain scoring
Assessment of interobserver agreement for each domain of the Odesa Criteria 2026 (OC26), including morphology, serology, clinical features, and histology. Agreement will be quantified using Cohen's kappa (κ) statistics for categorical items and intraclass correlation coefficients (ICC) for continuous or ordinal components. The analysis evaluates reproducibility of domain-level scoring among independent reviewers.
Time frame: At completion of baseline diagnostic workup
Diagnostic performance of individual OC26 domains
Evaluation of the diagnostic performance of each OC26 domain (morphology, serology, clinical, histology) in identifying autoimmune pancreatitis. For each domain, sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve (AUC) will be calculated using final clinical diagnosis as the reference standard.
Time frame: At completion of baseline diagnostic workup
ROC curve analysis for total OC26 score
Receiver operating characteristic (ROC) curve analysis of the total OC26 score to determine its discriminative ability for diagnosing autoimmune pancreatitis. The area under the curve (AUC) will be calculated, and performance will be compared across predefined subgroups.
Time frame: At completion of baseline diagnostic workup
Optimal cut-off value for OC26 total score
Determination of the optimal diagnostic cut-off for the OC26 total score using Youden's index and other threshold-optimization methods. Sensitivity, specificity, and accuracy at the optimal cut-off will be reported.
Time frame: At completion of baseline diagnostic workup
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.